Collavant N2
Also known as: Collavant N2, Undenatured Type II Collagen, Native Type II Collagen
Overview
Collavant N2 is a proprietary form of native (undenatured) type II collagen, a major structural protein found in cartilage, extracted from chicken sternum. Developed by Bioiberica, it is designed as a joint health supplement to support cartilage integrity and function. Its primary applications include reducing pain and stiffness associated with osteoarthritis (OA) and improving overall joint mobility. Key characteristics of Collavant N2 include its low effective dose of 40 mg/day, its compatibility with other joint health ingredients like Boswellia serrata, and its potential for rapid onset of pain relief. Research supporting Collavant N2's efficacy includes randomized controlled trials (RCTs) and systematic reviews on native type II collagen, indicating a moderate level of evidence for its benefits in joint health.
Benefits
Collavant N2 offers significant benefits for joint health, particularly in individuals with osteoarthritis. Clinical studies have shown a significant reduction in knee osteoarthritis pain, with improvements measured by the Visual Analog Scale (VAS) starting as early as 5 days when combined with Boswellia serrata. In women with knee OA, 40 mg/day of Collavant N2 for 6 weeks led to a 44.8% improvement in WOMAC pain scores, increased knee range of motion, and a 10.4% enhancement in 6-minute walk distance. These improvements are considered clinically meaningful. Beyond pain reduction, Collavant N2 also helps reduce joint stiffness and improve physical function. While efficacy has been particularly demonstrated in female populations with knee osteoarthritis, the benefits are generally applicable to joint health support. The rapid onset of pain relief and sustained improvements over several months highlight its potential as an effective intervention for OA symptoms.
How it works
Native type II collagen, including Collavant N2, is believed to exert its effects primarily through a mechanism known as oral tolerance. When consumed, the undenatured collagen interacts with immune cells in the gut-associated lymphoid tissue (GALT). This interaction modulates the immune system, specifically reducing autoimmune responses that contribute to cartilage degradation and inflammation within the joints. By dampening these immune-mediated attacks on cartilage, Collavant N2 helps to preserve joint integrity and reduce symptoms of osteoarthritis. The undenatured form of the collagen is crucial as it retains specific epitopes necessary for this immune modulation, allowing it to act on the body's immune system to protect joint tissues.
Side effects
Collavant N2 is generally well-tolerated, with no significant adverse effects reported in clinical trials at the recommended dose of 40 mg/day. Common, uncommon, or rare side effects have not been documented in the available research. There are no known significant drug interactions associated with Collavant N2. Specific contraindications have not been reported, but caution is advised for individuals with known chicken allergies, as the product is derived from chicken sternum. While evidence supports its use in women with osteoarthritis, data on other specific populations is more limited. Overall, its safety profile appears favorable, making it a suitable option for long-term joint health support within the studied dosage range.
Dosage
The minimum effective dose and optimal dosage for Collavant N2 are consistently reported as 40 mg/day. This dosage has been used in clinical studies and is recommended for daily oral administration. There is no clearly established maximum safe dose, as studies have primarily focused on the 40 mg/day regimen. Collavant N2 can be taken once daily, typically in oral capsule form. It is often found in formulations combined with other joint-supportive ingredients, such as Boswellia serrata, which has shown synergistic effects. As an undenatured protein, its bioactivity is preserved, and no specific cofactors are reported to be required for its absorption or efficacy.
FAQs
Is Collavant N2 safe for long-term use?
Current evidence from clinical trials up to 3 months indicates good safety and tolerability, suggesting it is safe for continued use within this timeframe. Longer-term studies are ongoing.
How soon can benefits be expected?
Pain relief may begin as early as 5 days, particularly when combined with Boswellia serrata, with continued improvement observed over several weeks of consistent use.
Can it be combined with other supplements?
Yes, Collavant N2 has been safely and effectively combined with other joint health supplements, such as Boswellia serrata, demonstrating synergistic benefits.
Is it effective without exercise?
Benefits have been observed both with and without concurrent exercise. However, incorporating exercise into a joint health regimen may enhance overall outcomes.
Is it suitable for men?
While most studies have focused on women with osteoarthritis, the mechanism of action suggests potential benefits for men as well. Further research specifically in men is needed.
Research Sources
- https://nutraceuticalbusinessreview.com/clinical-study-confirms-bioiberica-s-collavant-n2-collagen-combined-with-boswellia-serrata-reduces-joint-discomfort-in-just-5-days-201662 – This multicentric randomized controlled trial (n=40) investigated the combination of 40 mg Collavant N2 with 100 mg Boswellia serrata in knee OA patients over 3 months. It found significant reduction in VAS pain scores starting at day 5 and sustained through day 90, alongside improved joint function and no reported side effects. The study highlights the rapid onset of pain relief with this combination.
- https://www.wholefoodsmagazine.com/articles/16876-research-updates-athletic-performance-menstrual-symptoms-obesity-skin-health-and-more – This source references research updates, including a study on Collavant N2. It indicates that 40 mg/day of Collavant N2 for 6 weeks in women with knee OA led to a 44.8% improvement in WOMAC pain scores, increased knee range of motion, and a 10.4% improvement in 6-minute walk distance, demonstrating clinically relevant outcomes.
- https://www.ijoro.org/index.php/ijoro/article/download/3231/1830/17554 – This systematic review and meta-analysis, while not specific to Collavant N2, supports the efficacy of native type II collagen in reducing osteoarthritis symptoms and improving function. It consolidates findings from multiple randomized controlled trials, confirming the clinical benefits of undenatured type II collagen in joint health with a low risk of adverse events.
- https://www.nutritioninsight.com/news/empowering-mobility-bioibericas-collavant-n2-collagen-improves-womens-joint-health.html – This article discusses Bioiberica's Collavant N2 and its role in improving women's joint health. It highlights findings from a clinical study showing that 40 mg/day of Collavant N2 significantly improved WOMAC pain scores and physical function in women with knee osteoarthritis.
- https://www.bioiberica.com/en/media/news/healthcare/women-only-clinical-study-reveals-our-collavant-n2-native-undenatured-type-ii-collagen-shows-joint-health-benefits-40-mg – This source details a women-only clinical study on Collavant N2, confirming its joint health benefits at a 40 mg dose. The study demonstrated improvements in pain, range of motion, and functional mobility in women with knee osteoarthritis, reinforcing the ingredient's efficacy in this demographic.
